Tanshinone I Inhibits Oxidative Stress-Induced Cardiomyocyte Injury by Modulating Nrf2 Signaling

  • Front Pharmacol. 2021 May 18;12:644116. doi: 10.3389/fphar.2021.644116.
Yu-Ting Wu  1  2 Ling-Peng Xie  1  3  4 Yue Hua  1  3  4 Hong-Lin Xu  1  3  4 Guang-Hong Chen  1  3  4 Xin Han  1  3  4 Zhang-Bin Tan  1  5 Hui-Jie Fan  1  6 Hong-Mei Chen  1  3  4 Jun Li  1  3 Bin Liu  1  5 Ying-Chun Zhou  1  3  4
Affiliations
  • 1. School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
  • 2. Department of Traditional Chinese Medicine, Binzhou Medical University Hospital, Binzhou, China.
  • 3. Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • 4. Department of Traditional Chinese Medicine, Nanfang Hospital (Zengcheng Branch), Southern Medical University, Guangzhou, China.
  • 5. Guangzhou Institute of Cardiovascular Disease, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • 6. TCM Health Construction Department of Yangjiang People's Hospital, Yangjiang, China.
Abstract

Cardiovascular Disease, a disease caused by many pathogenic factors, is one of the most common causes of death worldwide, and oxidative stress plays a major role in its pathophysiology. Tanshinone I (Tan I), a natural compound with cardiovascular protective effects, is one of the main active compounds extracted from Salvia miltiorrhiza. Here, we investigated whether Tan I could attenuate oxidative stress and oxidative stress-induced cardiomyocyte Apoptosis through Nrf2/MAPK signaling in vivo and in vitro. We found that Tan I treatment protected cardiomyocytes against oxidative stress and oxidative stress-induced Apoptosis, based on the detection of relevant oxidation indexes such as Reactive Oxygen Species, superoxide dismutase, malondialdehyde, and Apoptosis, including cell viability and apoptosis-related protein expression. We further examined the mechanisms underlying these effects, determining that Tan I activated nuclear factor erythroid 2 (NFE2)-related factor 2 (Nrf2) transcription into the nucleus and dose-dependently promoted the expression of Nrf2, while inhibiting MAPK signaling activation, including p38 MAPK, SAPK/JNK, and ERK1/2. Nrf2 inhibitors in H9C2 cells and Nrf2 knockout mice demonstrated aggravated oxidative stress and oxidative stress-induced cardiomyocyte injury; Tan I treatment suppressed these effects in H9C2 cells; however, its protective effect was inhibited in Nrf2 knockout mice. Additionally, the analysis of surface plasmon resonance demonstrated that Tan I could directly target Nrf2 and act as a potential Nrf2 agonist. Collectively, these data strongly indicated that Tan I might inhibit oxidative stress and oxidative stress-induced cardiomyocyte injury through modulation of Nrf2 signaling, thus supporting the potential therapeutic application of Tan I for oxidative stress-induced CVDs.

Keywords
Nrf2; Tanshinone I; apoptosis; cardiomyocytes; oxidative stress.
Products